Aryl H-Phosphonates 18. Synthesis, properties, and biological activity of 2',3'-dideoxynucleoside (N-heteroaryl)phosphoramidates of increased lipophilicity.

Recently, AZT (N-pyridyl)phosphoramidates were reported as a new type of potential anti-HIV therapeutics. In continuation of that work, here we present new (N-heteroaryl)phosphoramidate derivatives of antiviral 2',3'-dideoxynucleosides containing other types of N-heteroaryl moieties, particularly those with higher lipophilicity. The present studies comprise mechanistic investigations using (31)P NMR correlation analysis, which permitted improvements in the synthetic procedures. The obtained compounds were tested in biological systems to establish their cytotoxicity and anti-HIV activity. The results were analyzed with respect to possible correlations between biological and physico-chemical properties of the phosphoramidates studied, to get some insight into their antiviral mode of action.

Myristoylated derivatives of 2',3'-didehydro-2',3'-dideoxythymidine (stavudine) bi-functional prodrugs with potent anti-HIV-1 activity and low cytotoxicity.

BACKGROUND: To improve in vitro antiviral activity and selectivity of stavudine (d4T), a range of its bi-functional prodrugs, 5'-O-myristoylated derivatives, have been synthesized. METHODS: Stavudine 5'-O-myristoylated esters were synthesized using modified Parang's procedure. The cytotoxicity and anti-HIV activity was evaluated in the established MT-4 cell line. The level of p24 protein in culture medium was assayed, and EC50 and EC90 values were determined. RESULTS: Excellent anti-HIV activity was obtained for stavudine derivatives 2',3'-didehydro-2',3'-dideoxy-5'-O-(11-thioethylundecanoyl) thymidine, 2',3'-didehydro-2',3'-dideoxy-5'-O-(12-thioethyldodecanoyl) thymidine and 5'-O-(12-azidododecanoyl)-2',3'-didehydro-2',3'-dideoxythymidine with C10 and C11 alkyl chains bearing thioethyl- and azido- substituents. These prodrugs were more potent than the parent stavudine, as is clear from their EC50 values: 2',3'-didehydro-2',3'-dideoxy-5'-O-(11-thioethylundecanoyl) thymidine (R=CO(CH2)10SC2H5, EC50 0.06 µM), 2',3'-didehydro-2',3'-dideoxy-5'-O-(12-thioethyldodecanoyl) thymidine (R=CO(CH2)11SC2H5, EC50 0.09 µM) and 5'-O-(12-azidododecanoyl)-2',3'-didehydro-2',3'-dideoxythymidine (R=CO(CH2)11N3, EC50 0.06 µM), while 50% cytotoxic concentration was >16.65 µM, >7.5 µM and >18.53 µM, respectively. CONCLUSIONS: Overall data demonstrate that compounds 2',3'-didehydro-2',3'-dideoxy-5'-O-(11-thioethylundecanoyl) thymidine, 2',3'-didehydro-2',3'-dideoxy-5'-O-(12-thioethyldodecanoyl) thymidine and 5'-O-(12-azidododecanoyl)-2',3'-didehydro-2',3'-dideoxythymidine are very potent and selective anti-HIV agents and could be useful in treatment of HIV infections of the central nervous system.

Aryl H-phosphonates 17: (N-aryl)phosphoramidates of pyrimidine nucleoside analogues and their synthesis, selected properties, and anti-HIV activity.

New synthetic protocol for the preparation of nucleoside 5'-(N-aryl)phosphoramidate monoesters 4 was developed. It consisted of a condensation of the corresponding nucleoside 5'-H-phosphonates with aromatic- or heteroaromatic amines promoted by diphenyl phosphorochloridate, followed by oxidation of the produced H-phosphonamidates with iodine/water. 5'-(N-Aryl)phosphoramidate monoesters derived from 3'-azido-3'-deoxythymidine (AZT) or 2',3'-dideoxyuridine (ddU) nucleosides and various aromatic and heteroaromatic amines were evaluated as potential anti-HIV drugs. It was found that these compounds act most likely as pronucleotides and that some of them have therapeutic indices superior to those of the reference AZT.

Synthesis and anti-HIV properties of novel 6-phenylselenenyl-5-propyluracils.

Novel 6-phenylselenenyl-5-propyluracils were synthesized from 5-propyluracil with the use of regioselective synthesis to give 1-[(2-hydroxyethoxy)-methyl]-6-phenylselenenyl-5-propyluracil (6), 1-ethoxymethyl-6-phenylselenenyl-5-propyluracil (9) and 1-benzyloxymethyl-6-phenylselenenyl-5-propyluracil (10). Interaction of these compounds with recombinant HIV-1 reverse transcriptase (RT) was evaluated using a non-isotopic colorimetric method. Compounds 9 and 10 exerted potent HIV RT inhibition (IC(50) 0.06 and 0.05 microM respectively) while compound 6 showed moderate inhibition (IC(50) = 3.5 microM). Potent anti-HIV-1 activity in MT-2 cells inoculated by a syncythia-inducing HIV-1 (cat #3 strain) laboratory isolate was exerted by compounds 9 and 10 (EC(50) 0.62 microM and 0.025 microM, respectively), while compound 6 showed only moderate activity (IC(50) = 4.1 microM). In addition, compound 10 showed very good in vitro therapeutic index (TI > 2046), indicating that it is a potential anti-HIV/AIDS drug.

[Absence of echoviral RNA sequences in medulla oblongata samples taken from patients who died of ALS]. / Nieobecnosc sekwencji echowirusowego RNA w skrawkach rdzeni przedluzonych pacjentów zmarlych z powodu stwardnienia bocznego zanikowego.

BACKGROUND AND PURPOSE: The role of viral infection in the pathogenesis of ALS has been raised many times in the previous papers. The presence of an enterovirus genome has previously been confirmed using PCR RT and PCR in situ in spinal cord tissue samples taken from patients who died of ALS. Viral genome sequencing has also been used to show 91% and 88% homogeneity with ECHO 6 and 7 viruses, respectively. A year later the same method did not confirm the presence of the virus in spinal cord fragments taken from 30 patients who died of ALS nor in an 18 person control group. The present study was aimed to find persistent ECHO 6 and 7 viral infections in tissue samples taken from patients who died of ALS. MATERIAL AND METHODS: RNA was isolated from frozen medulla oblongata samples taken from six patients who died of ALS (hospitalized in the Neurological Clinic CSK AM in the years 2000-2002). The presence of RNA was confirmed using RNA beta-actine. Oligo 2 and 3 as well as pEforward and pErevers primers were used for amplification. RESULTS: All samples returned negative results. CONCLUSIONS: In the samples studied no correlation was found between ECHO 6 and 7 viral infections and ALS.

Synthesis and biological activity of 1H-benzotriazole and 1H-benzimidazole analogues--inhibitors of the NTpase/helicase of HCV and of some related Flaviviridae.

To improve anti-helical activity of analogues of 1H-benzotriazole and 1H-benzimidazole their N-alkyl derivatives were synthesized and tested for antihelicase activity against enzymes of selected Flaviviridae including hepatitis C virus (HCV), West Nile virus (WNV), Dengue virus (DENV) and Japanese encephalitis virus (JEV). 1- and 2-alkyl derivatives of 4,5,6,7-tetrabromo-1H-benzotriazole were obtained by direct alkylation of 4,5,6,7-tetrabromo-1H-benzotriazole with the use of respective alkyl halides in the presence of KOH in methanol, to give a mixture of 1- and 2- isomers, which was separated by flash column chromatography in good yield. The proportion of isomers strongly depended on the reaction time and temperature. 1- and 2-hydroxyethyl and 1- and 2-chloroethyl derivatives of the tetrabromobenzo-triazole were synthesized with the use of 2-bromoethanol and 1-bromo-2-chloroethane respectively as alkylating agents. N-alkylation of this benzotriazole compound enhanced inhibitory activity and selectivity towards the helicase activity of HCV NTPase/helicase. The most active were the 2-methyl, 2-ethyl and 2-propyl derivatives (IC50 approximately 6.5 microM in the presence of DNA as a substrate). Derivatives of the benzotriazole in which hydroxyethyl or chloroethyl replaced the alkyl substituents lost their inhibitory activity. Brominated or methylated benzotriazole N(1) ribosides also did not exert helicase inhibitory activity. Although a number of N(1) and N(2) alkyl derivatives exerted good HCV and WNV helicase inhibitory activity when DNA was used as substrate, the activity was strongly decreased or even disappeared when RNA was used as substrate. The cytotoxicity tests in Vero and HeLa Tat cells showed a substantial decrease of cytotoxicity of N-alkyl derivatives as compared to the parent benzotriazole.

Inhibitors of the NTPase/helicases of hepatitis C and related Flaviviridae viruses.

Abstract: In the search for inhibitors of the non-structural protein 3 (NS3)-associated NTPase/helicase activities of the hepatitis C virus (HCV), and of the related West Nile Virus (WNV), and Japanese Encephalitis Virus (JEV), random screening of a broad range of unrelated low-molecular weight compounds revealed that 4,5,6,7-tetrabromo-1H-benzotriazole (TBBT) is a good inhibitor of the helicase activity of HCV and WNV NTPase/helicases (IC50 >> 20 mM and 1.7 mM with a DNA substrate), but a very weak inhibitor of the JEV enzyme (IC50 >> 200 mM). The synthesis of new TBBT derivatives was undertaken and their inhibitory activities against HCV, WNV, and JEV NTPase/helicases and cytotoxicities were examined. The N-alkyl derivatives showed good activity and lower cytotoxicity than TBBT.

[New antiretroviral medications in therapy of HIV infections]. / Nowe leki antyretrowirusowe w leczeniu zakazen HIV.

Therapeutic options continue to expand with the development of new drugs and new strategies for using them. This report describes progress in laboratory and clinical trials of new inhibitors of reverse transcriptase and viral protease, turning special attention on their efficacy for therapy of patient with drug resistant viruses for current therapies. The second group is a new class of anti-HIV drugs called "fusion inhibitors" or "viral entry inhibitors" The fusion inhibitors halt HIV at a unique point in the virus life cycle blocking attachment of virus to the membrane of target cells. All of the described drugs are not potent enough to eradicate the virus. Diminished toxicity of proposed new antiretroviral substances, more tolerable regimens easier for patients and efficacy against resistant viruses to currently used drugs are giving hope for further prolongation of life of HIV infected patients.

[Laboratory tests for HIV infection]. / Diagnostyka laboratoryjna zakazen HIV.

This report describes commercially available tests for HIV diagnosis. It evaluates the sensitivity and specificity of tests and provides guidance for interpreting the test results. How use of them in HIV diagnosis is dependent on which kind of test was used, when the proper technique can to be used and how to interpret the results. The following diagnostic techniques are described: antibody related (EIA and Western blot), genetic test (PCR), viral protein estimation (p24 Ag), cell and viral culture.